Anifrolumab (Saphnelo)

Type I interferon receptor antagonist (monoclonal antibody)

Anifrolumab (Saphnelo)

Forms and strengths
Form: TabletStrength: 300 mg/2 mL (intravenous vial), 120 mg/0.8 mL (subcutaneous autoinjector)
Print

Indication

  • Anifrolumab is used, in addition to standard therapy, to treat adults with active, autoantibody-positive systemic lupus erythematosus (SLE).
  • Anifrolumab has not been studied in patients with severe active lupus nephritis or severe active central nervous system lupus, and its use is not recommended in these situations.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.